BUSINESSSCMP WORLD
Wall Street funds back China’s WuXi AppTec as weight-loss drug orders soar
US global asset managers, including BlackRock, have increased stakes in China's WuXi AppTec, anticipating higher earnings from a surge in weight-loss drug manufacturing orders. Investors show growing interest in China’s contract development and manufacturing organizations and biotechnology sectors, as noted by HSBC's Linda Shu.
Mentioned
Related Signal
Adjacent reporting
- Wall Street funds back China’s WuXi AppTec as weight-loss drug orders soar
- Which company could become the Chinese Pfizer? Here are analysts’ top picks
- China sees revival of foreign investors through IPOs, convertibles: UBS
- China's biotech boom alarms Western lawmakers, investors
- Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals
- Which company could become the Chinese Pfizer? Here are analysts’ top picks